|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 351.27 USD | -0.61% |
|
-0.21% | +15.62% |
| 01-28 | InSysBio Announces the Extension of Collaboration with BeOne Medicines | CI |
| 01-15 | BeOne CEO on Business Strategy, Biotech Outlook | MT |
| Capitalization | 38.87B 32.76B 29.98B 28.49B 52.82B 3,528B 54.61B 346B 138B 1,696B 146B 143B 5,959B | P/E ratio 2025 * |
108x | P/E ratio 2026 * | 53.6x |
|---|---|---|---|---|---|
| Enterprise value | 36.5B 30.76B 28.15B 26.75B 49.6B 3,312B 51.27B 325B 130B 1,592B 137B 134B 5,595B | EV / Sales 2025 * |
6.89x | EV / Sales 2026 * | 5.56x |
| Free-Float |
96.17% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BeOne Medicines AG
| 1 day | -0.61% | ||
| 1 week | -0.21% | ||
| Current month | +3.20% | ||
| 1 month | +3.96% | ||
| 3 months | +2.22% | ||
| 6 months | +21.23% | ||
| Current year | +15.62% |
| 1 week | 340 |  | 358.38 |
| 1 month | 325.1 | | 358.38 |
| Current year | 304.78 | | 358.38 |
| 1 year | 196.45 | | 385.22 |
| 3 years | 126.97 | | 385.22 |
| 5 years | 118.18 | | 426.56 |
| 10 years | 23.6 | | 426.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Oyler
CEO | Chief Executive Officer | 57 | 2010-10-27 |
Xiao Bin Wu
PSD | President | 64 | 2018-03-31 |
Aaron Rosenberg
DFI | Director of Finance/CFO | 50 | 2024-07-21 |
| Director | Title | Age | Since |
|---|---|---|---|
John Oyler
CHM | Chairman | 57 | 2016-01-26 |
Michael Goller
BRD | Director/Board Member | 51 | 2015-03-31 |
Ranjeev Krishana
BRD | Director/Board Member | 52 | 2014-09-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.61% | -0.21% | +58.79% | +43.68% | 38.87B | |
| +0.02% | -2.05% | -15.20% | -6.86% | 46.14B | |
| +5.27% | +11.66% | +38.61% | +61.04% | 36.18B | |
| -2.89% | -12.52% | -11.80% | -20.49% | 30.05B | |
| +2.09% | +1.53% | +136.41% | +298.66% | 18.94B | |
| -1.27% | -6.69% | +26.55% | -5.36% | 13.55B | |
| -1.20% | +0.80% | +85.33% | +94.37% | 13.6B | |
| +0.07% | -0.75% | +167.10% | +116.28% | 13.66B | |
| +0.15% | -5.85% | +27,082.10% | +3,523.54% | 13.21B | |
| -4.96% | -24.50% | +29.30% | +89.65% | 12.03B | |
| Average | -1.19% | -3.97% | +2,759.72% | +419.45% | 23.62B | |
| Weighted average by Cap. | -0.83% | -2.51% | +1,554.34% | +250.02% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.3B 4.47B 4.09B 3.88B 7.2B 481B 7.44B 47.13B 18.82B 231B 19.87B 19.46B 812B | 6.44B 5.43B 4.97B 4.72B 8.75B 584B 9.05B 57.28B 22.87B 281B 24.15B 23.65B 987B |
| Net income | 330M 278M 254M 242M 448M 29.93B 463M 2.93B 1.17B 14.39B 1.24B 1.21B 50.56B | 698M 588M 539M 512M 949M 63.37B 981M 6.21B 2.48B 30.47B 2.62B 2.56B 107B |
| Net Debt | -2.37B -2B -1.83B -1.74B -3.23B -215B -3.34B -21.12B -8.43B -104B -8.91B -8.72B -364B | -3.04B -2.57B -2.35B -2.23B -4.14B -276B -4.28B -27.08B -10.81B -133B -11.42B -11.18B -467B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-11 | 351.27 $ | -0.61% | 110,821 |
| 26-02-10 | 353.43 $ | +1.31% | 173,166 |
| 26-02-09 | 348.85 $ | -1.43% | 247,183 |
| 26-02-06 | 353.92 $ | +1.99% | 269,697 |
| 26-02-05 | 347.00 $ | -1.42% | 420,147 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ONC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition